OTTMUSG00000019256 Inhibitors

Inhibiting LOC625713 isoform X1 involves targeting key pathways and molecular mechanisms that regulate its activity. The majority of the selected inhibitors act on the phosphoinositide 3-kinases (PI3K)/AKT/mTOR pathway, which is integral to the function of LOC625713 isoform X1. Rapamycin, for example, forms a complex with FKBP12 that inhibits mTOR, a central kinase in this pathway. This inhibition disrupts downstream signaling involving LOC625713 isoform X1, leading to its functional reduction. Similarly, everolimus and Torin 1 also target mTOR, but with varying mechanisms and specificities. Everolimus forms a complex with FKBP12 to inhibit mTOR, while Torin 1 is a selective inhibitor of both mTORC1 and mTORC2 complexes, leading to a decrease in LOC625713 isoform X1 activity.

Other inhibitors like Wortmannin and LY294002 specifically target PI3Ks, leading to a suppression of the entire PI3K/AKT/mTOR pathway. This suppression is crucial as it leads to the decreased activity of LOC625713 isoform X1. Triciribine, which targets AKT, and PP242, an ATP-competitive inhibitor of mTOR, also follow this inhibition strategy. Ku-0063794, PI-103, AZD8055, Palomid 529, and ZSTK474 further exemplify this approach. Ku-0063794 and AZD8055 are selective inhibitors of mTORC1 and mTORC2, whereas PI-103 and Palomid 529 are dual inhibitors of PI3K and mTOR. ZSTK474's inhibition of PI3K leads to reduced activity of downstream targets, including LOC625713 isoform X1. These inhibitors, through their specific actions on different components of the PI3K/AKT/mTOR pathway, effectively reduce the functional activity of LOC625713 isoform X1, highlighting the pivotal role of this signaling pathway in regulating the protein's activity.